Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF15.82
-0.08 (-0.50%)
CH SIX Healthcare Biotechnology
Address
Hohenrainstrasse 24 4133
Pratteln, BL, CH
Pratteln, BL, CH
CEO
Dario Eklund
Website
santhera.com
IPO
2006-11-03
ISIN CH1276028821
Also trades on
London Stock Exchange · 0QN1.L (CHF)
Other OTC · SPHDF (USD)
Swiss Exchange · SANN.SW (CHF)
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF15.82
-0.08 (-0.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
88.9K
Beta
-0.31
Float Shares
11.28M
Free Float %
77.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.13% | -0.37% | -4.12% | -3.55% | +33.61% | +34.27% | +23.86% | +91.54% | -20.10% | -97.82% | -98.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.82
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.79
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+97.3% ★ Q4'25: -46.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-2.4% Q4'25: -111.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-60.3% Q4'25: -26.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-49.0% Q4'25: -4.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-59.5% Q4'25: -14.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+14.4% Q4'25: +20.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.04× Q4'25: 50.92× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.32M
est: 5.65M (-23.5%)
|
19.03M
est: 19.00M (+0.2%)
|
22.94M
est: 22.90M (+0.2%)
|
31.66M
est: 32.00M (-1.1%)
|
75.38M
est: 77.00M (-2.1%)
|
15.01M
est: 15.00M (+0.1%)
|
-1.60M
est: 5.35M (-129.8%)
|
7.47M
est: 5.16M (+44.8%)
|
103.41M
est: 113.59M (-9.0%)
|
39.12M
est: 31.95M (+22.4%)
|
77.19M
est: 77.36M (-0.2%)
|
96.35M
96.35M – 96.35M
+24.5% YoY
|
119.55M
119.55M – 119.55M
+24.1% YoY
|
140.50M
140.50M – 140.50M
+17.5% YoY
|
| EBITDA |
4.06M
est: -723.8K (+660.3%)
|
-29.92M
est: -2.43M (-1,129.2%)
|
-44.05M
est: -2.93M (-1,401.5%)
|
-45.62M
est: -4.10M (-1,012.8%)
|
-7.54M
est: -9.86M (+23.6%)
|
-53.43M
est: -1.92M (-2,680.3%)
|
-34.57M
est: -685.8K (-4,940.9%)
|
-46.78M
est: -661.3K (-6,973.6%)
|
79.17M
est: -1.29M (+6,236.0%)
|
-15.89M
est: -362.9K (-4,277.6%)
|
-32.13M
est: -878.8K (-3,555.8%)
|
-1.09M
-1.09M – -1.09M
-24.5% YoY
|
-1.36M
-1.36M – -1.36M
-24.1% YoY
|
-1.60M
-1.60M – -1.60M
-17.5% YoY
|
| EBIT |
2.95M
est: -920.2K (+420.0%)
|
-33.18M
est: -3.09M (-972.2%)
|
-47.43M
est: -3.73M (-1,171.8%)
|
-49.36M
est: -5.21M (-847.1%)
|
-12.31M
est: -12.54M (+1.8%)
|
-60.57M
est: -2.44M (-2,379.1%)
|
-38.29M
est: -871.8K (-4,292.4%)
|
-50.43M
est: -840.7K (-5,898.1%)
|
76.13M
est: -6.91M (+1,201.4%)
|
-21.53M
est: -1.94M (-1,007.5%)
|
-37.82M
est: -4.71M (-703.2%)
|
-5.86M
-5.86M – -5.86M
-24.5% YoY
|
-7.28M
-7.28M – -7.28M
-24.1% YoY
|
-8.55M
-8.55M – -8.55M
-17.5% YoY
|
| Net Income |
5.95M
est: -454.43M (+101.3%)
|
-35.42M
est: -622.50M (+94.3%)
|
-51.53M
est: -926.13M (+94.4%)
|
-54.19M
est: -783.74M (+93.1%)
|
-18.97M
est: 4.55M (-517.0%)
|
-67.66M
est: -481.17M (+85.9%)
|
-55.53M
est: -191.10M (+70.9%)
|
-71.08M
est: -71.66M (+0.8%)
|
54.78M
est: 76.69M (-28.6%)
|
-41.97M
est: -28.70M (-46.3%)
|
-49.24M
est: -28.70M (-71.6%)
|
-7.81M
-7.81M – -7.81M
+72.8% YoY
|
3.32M
3.32M – 3.32M
+142.5% YoY
|
12.23M
12.23M – 12.23M
+268.6% YoY
|
| SGA |
16.60M
est: -8.78M (+289.1%)
|
30.86M
est: -29.53M (+204.5%)
|
42.94M
est: -35.59M (+220.7%)
|
40.25M
est: -49.73M (+180.9%)
|
39.28M
est: -119.67M (+132.8%)
|
23.91M
est: -23.31M (+202.6%)
|
22.06M
est: -8.32M (+365.1%)
|
25.42M
est: -8.02M (+416.9%)
|
30.97M
est: -203.88M (+115.2%)
|
29.87M
est: -57.35M (+152.1%)
|
30.06M
est: -138.86M (+121.7%)
|
-172.94M
-172.94M – -172.94M
-24.5% YoY
|
-214.58M
-214.58M – -214.58M
-24.1% YoY
|
-252.18M
-252.18M – -252.18M
-17.5% YoY
|
| EPS |
11.10
est: -39.95 (+127.8%)
|
-56.50
est: -54.73 (-3.2%)
|
-82.19
est: -81.42 (-0.9%)
|
-78.63
est: -68.90 (-14.1%)
|
-17.26
est: 0.40 (-4,415.0%)
|
-50.81
est: -42.30 (-20.1%)
|
-16.25
est: -16.80 (+3.3%)
|
-11.67
est: -6.30 (-85.2%)
|
5.18
est: 5.89 (-12.1%)
|
-3.69
est: -2.21 (-67.3%)
|
-3.78
est: -2.21 (-71.4%)
|
-0.60
-0.60 – -0.60
+72.8% YoY
|
0.26
0.26 – 0.26
+142.5% YoY
|
0.94
0.94 – 0.94
+268.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-69.95M
OE per share TTM
-5.76
Owner's Yield
-32.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.01% | 703.3K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-484.8K
Shares Outstanding
14.53M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dario Eklund | Chief Executive Officer | 1M | male |
| Thomas Meier | Founder & Chairman | 200.0K | — |
| Geert Jan van Daal | Chief Commercial Officer | — | male |
| Marc Schrader | Chief Technology Officer | — | male |
| Andreas Missy | Executive Vice President of Corporate Planning & Business Development | — | male |
| Oliver Kronenberg | Chief Legal Officer & Corporate Secretary | — | — |
| Oliver Strub | Head of Compliance | — | male |
| Sarah Holmes-Klotz | Global Head of People & Culture | — | female |
| Shabir Hasham | Chief Medical Officer | — | male |
| Neville Kodkani | Head of Global Marketing & Partner Management | — | male |
| Catherine Ann Isted | Chief Financial Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SANN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
